Review of growth hormone therapy in adolescents and young adults with Prader–Willi syndrome

References

• Deal CL, Tony M, Hoybe C, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87
   PubMed Web of Science ®Google Scholar
• Crino A, Di Giorgio G, Livieri C, et al. A survey on Prader-Willi syndrome in the Italian population: prevalence of historical and clinical signs. J Pediatr Endocrinol Metab 2009;22:883-93
   PubMedGoogle Scholar
• Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012;14:10-26
   PubMed Web of Science ®Google Scholar
• Tuysuz B, Kartal N, Erener-Ercan T, et al. Prevalence of Prader-Willi syndrome among infants with hypotonia. J Pediatr 2014;164:1064-7
   PubMed Web of Science ®Google Scholar
• Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792-8
   PubMed Web of Science ®Google Scholar
• Vogels A, Van Den Ende J, Keymolen K, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Europ J Med Genet 2004;12:238-40
   Google Scholar
• Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97
   PubMed Web of Science ®Google Scholar
• Bridges N. What is the role of growth hormone in Prader Willi syndrome? Arch Dis Child 2014;99:166-70
   PubMed Web of Science ®Google Scholar
• Lionti T, Reid SM, Rowell MM. Prader-Willi syndrome in Victoria: mortality and causes of death. J Paediatr Child Health 2012;48:506-11
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Human growth hormone (somatropin) for the treatment of growth failure in children. Review of NICE technology appraisal guidance 42. 2010
   Google Scholar
• Myers SW, Whitman BY, Carrel AL, et al. Two years of Growth Hormone therapy in young children with Prader-Willi syndrome. Am J Med Genet 2007;143A(443):448
   Google Scholar
• Carrell AL, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004;145:744-9
   PubMedGoogle Scholar
• Reus L, van Vlimmeren LA, Staal JB, et al. The effect of growth hormone treatment or physical training in Prader-Willi syndrome: a systematic review. Neurosci Biobehav Rev 2012;36:1817-38
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Health for the World’s Adolescents. A second chance in the second decade. 2014. Available from: http://apps.who.int/adolescent/second-decade/ [last accessed 14/10/14]
   Google Scholar
• Sizonenko PC. Hormonal changes during normal puberty. Am J Dis Child 1978;132:704-12
   PubMedGoogle Scholar
• Sharkia M, Michaud S, Berthier MT, et al. Thyroid function from birth to adolescence in Prader-Willi syndrome. J Pediatr 2013;163:800-5
   PubMed Web of Science ®Google Scholar
• Burman P, Ritze EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787-99
   PubMed Web of Science ®Google Scholar
• Oto Y, Obata K, Matsubara K, et al. Growth hormone secretion and its effect on height in pediatric patients with different genotypes of Prader-Willi syndrome. Am J Med Genet 2012;158A:1477-80
   PubMedGoogle Scholar
• Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal boys and girls. J Clin Endocrinol Metab 1991;73(2):428-35
   PubMedGoogle Scholar
• Coupaye M, Lorenzini F, Lloret-Linares C, et al. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab 2013;98:E328-35
   PubMed Web of Science ®Google Scholar
• Bakker NE, Kuppens RJ, Siemensma EPC, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013;98:4013-22
   PubMedGoogle Scholar
• Craig ME, Cowell CT, Larsson P, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-85
   PubMed Web of Science ®Google Scholar
• Haqq AM, Stader LL, Jackson RH, et al. Effects of growth hormone on pulmonary function, sleep quality, behaviour, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:2206-12
   PubMed Web of Science ®Google Scholar
• Miller J, Silverstein J, Shuster J, et al. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab 2006;91:413-17
   PubMed Web of Science ®Google Scholar
• Quaio CRDC, de Almeida TF, Albano LMJ, et al. A clinical follow-up of 35 Brazilian patients with Prader-Willi syndrome. Clinics. 2012;67:917-21
   Google Scholar
• Sipila I, Sintonen H, Hietanen H, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Pediatr 2010;99:1712-18
   PubMedGoogle Scholar
• Whitman BY, Myers S, Carrel A, et al. The behavioural impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2 year, controlled study. Pediatrics 2002;109:e35
   PubMedGoogle Scholar
• Grugni G, Crino A, Bosio L, et al. The Italian national survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet 2008;146A:861-72
   PubMedGoogle Scholar
• Butler MG, Smith BK, Lee J, et al. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm IGF Res 2013;23:81-7
   PubMed Web of Science ®Google Scholar
• Hoybye C, Hilding A, Jacobsson H, et al. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002;87(8):3590-7
   PubMedGoogle Scholar
• Hoybye C. Endocrine and metabolic aspects of Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004;14:1-15
   PubMed Web of Science ®Google Scholar
• Mogul HR, Lee PDK, Whitman BK, et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat and serum triiodothyronine without glucose impairment: results from the United States Multicenter Trial. J Clin Endocrinol Metab 2008;93:1238-45
   PubMed Web of Science ®Google Scholar
• Sode-Carlsen R, Farholt S, Rabbe KF, et al. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomised, placebo-controlled study. J Clin Endocrinol Metab 2010;95:4943-50
   PubMedGoogle Scholar
• Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf) 2012;77:86-93
   PubMed Web of Science ®Google Scholar
• Gordon-Larsen P, Adair LS, Nelson MC, et al. Five-year obesity incidence in the transition period between adolescence and adulthood: the National Longitudinal Study of Adolescent Health. Am J Clin Nutr 2004;80:569-75
   PubMed Web of Science ®Google Scholar
• Eiholzer U, Grieser J, Schlumpf M, et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007;68:178-84
   PubMedGoogle Scholar
• Veltman M, Craig EE, Bolton PF. Autism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic review. Psychiatr Genet 2005;15:243-54
   PubMed Web of Science ®Google Scholar
• Boer H, Holland A, Whittington J, et al. Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparentaldisomy. Lancet 2002;359:135-6
   PubMed Web of Science ®Google Scholar
• Steinhausen HC, Eiholzer U, Hauffa BP, et al. Behavioural and emotional disturbances in people with Prader-Willi syndrome. J Intellect Disabil Res 2004;48:47-62
   PubMed Web of Science ®Google Scholar
• Caliandro P, Grugni G, Padua L, et al. Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. J Paediatr Child Health 2007;43:826-30
   PubMed Web of Science ®Google Scholar
• Dykens EM. Maladaptive and compulsive behaviour in Prader-Willi syndrome: new insights from older adults. Am J Ment Retard 2004;109:142-53
   PubMedGoogle Scholar
• Larcher V. ABC of adolescence: consent, competence and confidentiality. BMJ 2005;330:353-6
   PubMed Web of Science ®Google Scholar
• Timlin U, Hakko H, Heino R, Kyngäs H. A systematic narrative review of the literature: adherence to pharmacological and non-pharmacological treatments among adolescents with mental disorders. J Clin Nurs 2014;23(23-24):3321-34
   PubMedGoogle Scholar
• Hoybye C. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. Acta Pediatr 2007;96:410-13
   PubMed Web of Science ®Google Scholar
• Cook DM, Yuen KCJ, Biller BMK, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone deficient adults and transition patients-2009 update. Endocr Pract 2009;15(Suppl 2):1-29
   PubMedGoogle Scholar
• Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. J Pediatr Endocrinol 2013;2013(1):14
   Google Scholar
• Hartman ML. Physiological regulators of growth hormone secretion. In: Juul A, Jurgensen JOL, editors. Growth Hormone in Adults, 2nd edition. University Press, Cambridge; 2000;pp3-53
   Google Scholar
• Maghnie M, Aimaretti G, Bellone S, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-1 measurement. Eur J Endocrinol 2005;152:589-96
   PubMed Web of Science ®Google Scholar
• Corneli G, Di Somma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005;153:257-64
   PubMed Web of Science ®Google Scholar
• Clayton PE, Cuneo RC Juul A, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152:165-70
   PubMed Web of Science ®Google Scholar
• Miller L, Angulo M, Price D, et al. MR of the pituitary in patients with Prader-Willi syndrome: size determination and imaging findings. Pediatr Radiol 1996;26:43-7
   PubMed Web of Science ®Google Scholar
• Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 2000;355:610-13
   PubMed Web of Science ®Google Scholar
• Van Wijngaarden RFAL, Siemensma EPC, Festen DAM, et al. Efficacy and safety of long-term continuous Growth Hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94:4205-15
   Google Scholar
• Talebizadeh Z, Butler MG. Insulin resistance and obesity-related factors in Prader-Willy syndrome: comparison with obese subjects. Clin Genet 2005;67:230-9
   PubMed Web of Science ®Google Scholar
• Haqq AM, Muehlbauer MJ, Newgard CB, et al. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivitiy relative to body mass index. J Clin Endocrinol Metab 2011;96:e225-32
   Google Scholar
• Vandeleur M, Davey MJ, Nixon GM. Are sleep studies helpful in children with Prader-Willi syndrome prior to commencement of growth hormone therapy? J Pediatr Child Health 2013;49:238-41
   Google Scholar
• Oto Y, Tanaka Y Abe Y, et al. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A 2014;164:671-5
   Google Scholar
• Pfaffle R, Schwab KO, Marginean O, et al. Design of and first data from PATRO children, a multicentre non-interventional study of the long-term efficacy and safety of Omnitrope in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 2013;4:3-11
   PubMedGoogle Scholar
• Eiholzer U. Deaths in children with Prader-Willi syndrome. Horm Res 2005;63:33-9
   PubMedGoogle Scholar
• Nagai T, Obata K, Tonoki H, et al. Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without Growth Hormone treatment. Am J Med Genet 2005;136A:45-8
   Web of Science ®Google Scholar
• Tauber M, Diene G, Molinas C, et al. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet 2008;146A:881-7
   PubMedGoogle Scholar
• Steinberg L. Risk-taking in adolescence: new perspective from brain and behavioural science. Curr Dir Psychol Sci 2007;16:55-9
   Web of Science ®Google Scholar
• Schulze A, Mogensen H, Hamborg-Petersen G, et al. Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. Acta Pediatr 2007;90:455-9
   Google Scholar
• Wiren L, Boguszewski CL, Johannsson G. Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy. Clin Endocrinol 2002;57:235-9
   PubMedGoogle Scholar
• Schrander-Stumpel CT, Sinnema M, van den Hout L, et al. Healthcare transition in persons with intellectual disabilities: general issues, the Maastricht model, and Prader-Willi syndrome. Am J Med Genet C Semin Med Genet 2007;145:241-7
   Google Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult Growth Hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endo Metab 2006;91:1621-34
   PubMed Web of Science ®Google Scholar